Overview
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure
Status:
Completed
Completed
Trial end date:
2013-01-01
2013-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
50 patients of Acute-on-chronic liver failure (ACLF) will be enrolled and randomized into G-CSF+EPO or Placebo arms Treatment protocol To administer G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses). Standard medical therapy included as per requirement lactulose, bowel wash, albumin, terlipressin, antibiotics (if indicated) will be continued and recorded. Pentoxiphylline in alcoholic hepatitis and Tenofovir in Hep B reactivation Controls: Standard medical therapy will be given along with placebo in similar prefilled syringes. Follow up Physical examination will be done daily, after 1 week and at 4 weeks, at 2 months, at 3 months and at 6 months CBC on alternate day for 1 week, at end of 1 week and then at end of 4 weeks , at 2 months, at 3 months and at 6 months KFT on alternate day for 1 week, at end of 1 week and then at end of 4 weeks, at 2 months, at 3 months and at 6 months LFT along with PT/INR on alternate day for 1 week, at end of 1 week and then at end of 4 weeks, at 2 months, at 3 months and at 6 months AFP at baseline, after 4 weeks, at 3 months and at 6 months Liver regenerative potential efficacy testing at baseline and after 4 weeksPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Institute of Liver and Biliary Sciences, IndiaTreatments:
Epoetin Alfa
Lenograstim
Sargramostim
Criteria
Inclusion Criteria:All consecutive patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥ 5
mg/dL) and coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or
encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease
Exclusion Criteria:
- Age <12 or > 75 years
- Autoimmune disorders
- HCC
- Sepsis ( Any culture positive: blood, urine, any other obvious source of infection:
UTI, SBP)
- Multi organ failure
- Grade 4 HE
- HIV seropositivity / pregnancy
- Essential Hypertension
- Patients being taken up for transplant
- Refusal to participate in the study